Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL595358 | 0.82 | LTA4H (0.41) | LTA4HNOS1NOS3NOS2 | |
| SCHEMBL3800697 | 0.81 | LTA4H (0.33) | LTA4HNOS1NOS3NOS2 | |
| SCHEMBL379045 | 0.75 | MAOA (0.42) | — | |
| SCHEMBL18237306 | 0.71 | LTA4H (0.39) | LTA4H | |
| SCHEMBL30097254 | 0.71 | LTA4H (0.39) | LTA4H | |
| SCHEMBL594919 | 0.70 | KMT2A (0.50) | LTA4HNOS1NOS3NOS2 | |
| SCHEMBL283586 | 0.70 | KMT2A (0.50) | LTA4HNOS1NOS3NOS2 | |
| SCHEMBL1261014 | 0.70 | KMT2A (0.50) | LTA4HNOS1NOS3NOS2 | |
| SCHEMBL26891494 | 0.69 | LTA4H (0.45) | LTA4HNOS1NOS3NOS2 | |
| Hydrochloric Acid SCHEMBL2282696 | 0.68 | PMP22 (0.48) | LTA4HNOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391218-B1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10398781-B2 | Conjugate based systems for controlled drug delivery | SMARTCELLS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180064824-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2018-03-08 | — | — | US | disclosed |
| EP-2598522-A2 | RECOMBINANT LECTINS, BINDING-SITE MODIFIED LECTINS AND USES THEREOF | Smartcells, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015691-A2 | RECOMBINANT LECTINS, BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| EP-2408470-A1 | Soluble non-depot insulin conjugates and uses thereof | Smartcells, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2391215-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | Smartcells, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010107520-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010088286-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088261-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088294-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398781-B2 | Conjugate based systems for controlled drug delivery | SI, CSGALNACT1, CD44 | LTA4H 2400/4885NOS1 4237/4885NOS3 4530/4885 |
| US-20180064824-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | LTA4H 2400/4885NOS1 4237/4885NOS3 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.